Investment
Features
FeesSafety
Academy
More
Pluang+

KBR declares $0.165 quarterly dividend ahead of Mission Technology Solutions spin-off in January 2027

Company Fundamentals
14 Oct 2026
GlobeNewsWire
View Source
Neutral
KBR declares $0.165 quarterly dividend ahead of Mission Technology Solutions spin-off in January 2027

KBR announced a quarterly dividend of $0.165 per share payable on January 15, 2027, to shareholders of record on December 15, 2026. This dividend comes despite KBR's plan to spin off its Mission Technology Solutions business into a separate public company named Trinzic in January 2027. After the spin-off, both KBR and Trinzic will reassess their dividend policies. The spin-off will create two focused companies, with KBR continuing in industrial and energy markets and Trinzic serving national security and space sectors.

KBR's dividend declaration is the subject, with Pluang's Industrials sector data providing market context. Of 136 priced Industrials-sector US stocks tradable on Pluang, 89 rose and 41 fell today. Notable movers include EOSE at USD 2.35 with a 1-day change of +1.29%, MOD at USD 174.71 with +1.24%, and AGCO at USD 106.34 with -1.10%. This snapshot is as of Oct 14, 2026 17:01 WIB.

More News

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall Ltd. has emerged from stealth with $4 million in pre-seed funding to develop AI-powered autonomous attack agents that simulate real-world cyberattacks on enterprises. These agents start from outside the network with no insider access, contin...

Others
Bullish
59 minutes ago
Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...

Market News
Bullish
1 hour ago
FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...

Market News
Bullish
1 hour ago
DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global Inc. will announce its financial results for the third quarter ending September 30, 2026, on October 27 after the stock market closes. The company will hold a conference call and webcast to discuss the results, providing investors with ins...

Company Fundamentals
Neutral
1 hour ago
Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware introduced its Model Context Protocol (MCP) Server Protection solution to help organizations secure the integration layer where AI agents connect to enterprise applications and workflows. This new security tool provides visibility into MCP in...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App